Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moyer

Showing results (311-320 of 324) with videos related to

Pageof 33
Sort By:
Cancer Research|September 20, 2017
Upregulation of Cystathionine-β-Synthase in Colonic Epithelia Reprograms Metabolism and Promotes CarcinogenesisChes'Nique M Phillips, John R Zatarain, Michael E Nicholls, et al.
Biopharmaceutics & Drug Disposition|January 14, 2014
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitorAravind Basavapathruni, Edward J Olhava, Scott R Daigle, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Cancer Cell|July 12, 2011
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
Chemical Science|February 3, 2015
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition EnhancersF F Wagner, Y-L Zhang, D M Fass, et al.
Oncogene|April 8, 2014
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityN Li, K Lee, Y Xi, et al.
Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Cancer Cell|April 17, 2014
MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancerNicola Valeri, Chiara Braconi, Pierluigi Gasparini, et al.
Nature Chemical Biology|June 3, 2024
De novo design of proteins housing excitonically coupled chlorophyll special pairsNathan M Ennist, Shunzhi Wang, Madison A Kennedy, et al.
Pageof 33

Showing results (311-320 of 324) with videos related to

Sort By:
Pageof 33
Cancer Research|September 20, 2017
Upregulation of Cystathionine-β-Synthase in Colonic Epithelia Reprograms Metabolism and Promotes CarcinogenesisChes'Nique M Phillips, John R Zatarain, Michael E Nicholls, et al.
Biopharmaceutics & Drug Disposition|January 14, 2014
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitorAravind Basavapathruni, Edward J Olhava, Scott R Daigle, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Cancer Cell|July 12, 2011
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
Chemical Science|February 3, 2015
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition EnhancersF F Wagner, Y-L Zhang, D M Fass, et al.
Oncogene|April 8, 2014
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityN Li, K Lee, Y Xi, et al.
Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Cancer Cell|April 17, 2014
MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancerNicola Valeri, Chiara Braconi, Pierluigi Gasparini, et al.
Nature Chemical Biology|June 3, 2024
De novo design of proteins housing excitonically coupled chlorophyll special pairsNathan M Ennist, Shunzhi Wang, Madison A Kennedy, et al.
Pageof 33